LGI1 Antikörper (LRRCT Domain)

Produktnummer ABIN7885117

Der Kaninchen Polyklonal anti-LGI1 Antikörper wird verwendet zum Nachweis von LGI1 in Proben von Maus und Ratte. Er wurde validiert für WB.

Kurzübersicht für LGI1 Antikörper (LRRCT Domain) (ABIN7885117)

Target: LGI1 (Leucine-Rich, Glioma Inactivated 1 (LGI1))

Reaktivität: Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser LGI1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Güteklasse: Carrier-free

Produktdetails anti-LGI1 Antikörper

Bindungsspezifität: AA 206-218, LRRCT Domain

Verwendungszweck: A Rabbit Polyclonal Antibody to LGI1

Homologie: Mouse - identical, human - 12,13 amino acid residues identical

Aufreinigung: Affinity purified on immobilized antigen.

Immunogen: (C)YKKRKINSLSPKD, corresponding to amino acid residues 206-218 of rat LGI1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise:

WB: 1:200

FC: The optimal concentration should be determined by the user

ICC: The optimal concentration should be determined by the user

IHC: The optimal concentration should be determined by the user

IP: The optimal concentration should be determined by the user

Kommentare:

Negative Control: (ABIN7235886)

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: 0.2 mL double distilled water (DDW)

Konzentration: 1 mg/mL

Buffer: PBS pH 7.4

Konservierungsmittel: Without preservative

Lagerung: -20 °C

Informationen zur Lagerung: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Details zu LGI1

Target: LGI1 (Leucine-Rich, Glioma Inactivated 1 (LGI1))

Andere Bezeichnung: Leucine-rich glioma-inactivated protein 1

Hintergrund:

Synonyms: Leucine-rich glioma-inactivated protein 1, Epitempin-1, EPT

Description: The leucine-rich glioma inactivated (LGI) gene subfamily contains four highly conserved members (LGI1, 2, 3 and 4), which have been described in human, mouse and other mammalians. LGI1 is mainly expressed in the dentate gyrus and the CA3 field of the hippocampus1.The predicted structure of the LGI1 protein comprises, starting from the N-terminal, a signal peptide, four leucine-rich repeats (LRR) flanked on both sides by conserved cysteine clusters, and seven copies of a repeat of about 45 residues, named EPTP or EAR, probably forming a β-propeller structural domain. Both LRR and β-propeller domains mediate protein-protein interactions, each motif defining a distinct family of proteins.LGI1 is associated with a post-synaptic complex containing PSD-95 and ADAM22, a receptor associated with the post-synaptic membrane. Through specific binding to ADAM22, LGI1 participates in the control of synaptic strength at excitatory synapses, whose malfunction may result in epilepsy.LGI1 has been linked to several different clinical phenotypes including: malignant progression of glioma and autosomal dominant lateral temporal epilepsy, a rare familial partial epilepsy syndrome. The LGI1 gene has been shown to be frequently downregulated in malignant gliomas and to regulate invasiveness of some glioma cell lines by driving the expression of matrix metalloproteinases through the ERK 1/2 pathway. These findings suggest that LGI1 may serve as a tumor metastasis suppressor gene2. In addition, antibodies to LGI1 complexed with the KV1.1 potassium channel have been found in brain extracts from patients with limbic encephalitis3.

Gen-ID: 252892

UniProt: Q8K4Y5